What is Major Depressive Disorder?

Key Points (2026)

• Major depressive disorder prevalence in the United States has increased 60% in one decade: 8.2% (2013-2014) to 13.1% (August 2021-August 2023), affecting approximately 34 million Americans: CDC surveillance data show that during any given two-week period, 13.1% of U.S. adolescents and adults age 12 and older report depression symptoms. This staggering prevalence means one in eight Americans is currently experiencing depression. Rates are highest in adolescents (19.2%) and young adults (18.6%), with girls and women showing 23-26% higher rates than boys and men.
• Depression causes more functional impairment than other chronic conditions: 87.9% of individuals with depression report significant difficulty with work, school, family, or social activities due to symptoms, and depression is the second-leading cause of disability worldwide: Depression is not an inconvenience but a serious condition producing pervasive life disruption. The functional impairment is neurobiologically driven and is not resolved through willpower or effort alone.
• The economic burden of depression is staggering: depression costs the United States approximately 63 billion dollars annually in lost workplace productivity alone, with additional costs from healthcare, absenteeism, disability, and reduced earnings: Adults with depression are 3-5 times more likely to be unemployed. More than half of students with mental health disorders drop out of high school. The economic impact extends from individual earnings loss to organizational productivity loss to national workforce capacity.
• Major depressive disorder involves multiple neurobiological mechanisms: dysregulation of the hypothalamic-pituitary-adrenal (HPA) stress axis, altered serotonin and dopamine neurotransmission, glutamate dysregulation, neuroinflammation, reduced gray matter volume in prefrontal cortex and hippocampus, astrocyte and microglia dysfunction, and impaired synaptic plasticity: Depression is not a deficiency of willpower or motivation but a measurable alteration of brain chemistry, structure, and function. Understanding the neurobiology informs treatment: these mechanisms are what psychotherapy and medication address.
• Most people with depression do not receive treatment: only 40-50% of individuals with major depressive episodes access any treatment, creating a severe treatment gap where the burden of illness far exceeds treatment access: Despite depression being common and treatable, most Americans with depression do not receive professional help. The reasons include stigma, lack of awareness, cost, limited provider availability, and preference to manage alone. This treatment gap represents a critical public health failure.
• Depression is highly heritable with genetic vulnerability accounting for approximately 40% of risk, but environmental factors (trauma, stress, loss, medical illness, substance use) account for 60%, indicating both biological predisposition and modifiable risk factors: Depression results from gene-environment interactions. Genetic vulnerability makes individuals susceptible, but environmental triggering factors often precipitate episodes. This means both biological treatment (medication) and psychosocial treatment (addressing life circumstances and thinking patterns) are typically necessary.

What Is Major Depressive Disorder: Definition and Diagnostic Criteria

Major depressive disorder (MDD), also referred to as clinical depression, is a mental disorder characterized by persistent depressed mood or loss of interest or pleasure in activities, lasting at least two weeks, accompanied by multiple additional symptoms that cause significant distress or impairment in functioning. The condition is fundamentally different from normal sadness or grief: while sadness is an adaptive emotional response to loss or difficulty that gradually resolves over time, major depressive disorder is a persistent condition that does not resolve without intervention and causes severe life disruption.

According to the DSM-5 (the Diagnostic and Statistical Manual of Mental Disorders used in the United States), diagnosis of major depressive disorder requires that an individual experience at least five of nine specific symptoms during the same two-week period, representing a change from previous functioning. Additionally, at least one of the symptoms must be either depressed mood or loss of interest or pleasure. These symptoms must occur most of the day, nearly every day, and must cause clinically significant distress or impairment in social, occupational, or other important areas of functioning. The symptoms cannot be attributable to another medical condition, medication, substance use, or other mental disorder.

Types and Specifiers of Major Depressive Disorder

Major depressive disorder exists in various presentations classified by specifiers that further characterize the episode. Melancholic depression features profound loss of pleasure in most or all activities, failure of mood to improve even with positive circumstances, mood distinctly more severe than normal grief, morning worsening, early-morning waking, psychomotor retardation, and excessive guilt or weight loss. Atypical depression features paradoxical mood reactivity (mood can improve temporarily with positive events), marked weight gain or increased appetite, excessive sleep, leaden paralysis (sensation of heaviness in limbs), and significant interpersonal rejection sensitivity.

Psychotic depression involves major depressive episode with psychotic features including delusions or hallucinations. Mixed features specify episodes where at least three manic or hypomanic features occur during a major depressive episode (though if full manic or hypomanic episodes are present, bipolar disorder diagnosis applies instead). Perinatal depression occurs during pregnancy or the first month after birth. Seasonal pattern specifies recurrent episodes at particular times of year, typically fall and winter.

Major Depressive Disorder vs. Grief vs. Sadness vs. Dysthymia

A critical distinction in understanding major depressive disorder is differentiating it from normal sadness, grief, and related conditions. Normal sadness is an emotional response to loss, disappointment, or difficulty that is proportionate to the triggering event, improves gradually over days to weeks, and does not fundamentally impair functioning beyond temporary emotional pain. Grief from bereavement involves intense emotional pain from loss but typically decreases over weeks to months, involves ability to experience pleasure in some activities despite grief, and is contextualized to the loss.

Major depressive disorder, by contrast, involves depressed mood that persists regardless of circumstances, is typically more severe and disabling than normal sadness, involves anhedonia (loss of pleasure in multiple domains), causes functional impairment beyond emotional discomfort, and does not resolve through normal coping or time alone.

Additionally, persistent depressive disorder (dysthymia) is distinguished from major depressive disorder by being less severe but more chronic: dysthymia involves depressed mood most days for at least two years (or one year in children and adolescents) without meeting full criteria for major depressive episode. Dysthymia causes less acute distress but chronically undermines functioning. Some individuals experience both: double depression, where major depressive episodes occur during dysthymia, producing acute worsening on top of chronic baseline depression.

Comprehensive Symptom Picture: The Multiple Domains of Depression

While the DSM-5 provides diagnostic criteria, understanding major depressive disorder requires recognizing how symptoms manifest across multiple life domains. Depression is not simply sadness but a pervasive condition affecting mood, motivation, cognition, physical health, and social functioning simultaneously.

Mood and Emotional Symptoms

Persistent depressed mood: The core mood symptom is persistent sadness, emptiness, or hopelessness present most of the day, nearly every day. The depressed mood is not transient but stable and pervasive. Some individuals describe the feeling as numbness or emotional flatness rather than active sadness. The mood does not improve significantly with good events or positive circumstances. Unlike normal sadness that fluctuates throughout the day, depressive mood persists across situations and time.

Anhedonia and loss of pleasure: Anhedonia, the inability to experience pleasure or satisfaction, is often the most functionally devastating symptom. Activities that previously brought joy (hobbies, time with loved ones, food, sexual activity, achievement) now feel empty, flat, or pointless. Some individuals describe anhedonia as emotional numbness: they can engage in activities but feel nothing. Others describe activities as requiring overwhelming effort with no reward. The loss of pleasure often extends across multiple domains simultaneously: social withdrawal, loss of sexual interest, inability to enjoy entertainment or food, lack of satisfaction from accomplishment.

Hopelessness and helplessness: Most individuals with depression experience pervasive hopelessness: belief that their situation will not improve, that nothing can help, that the future is bleak. This hopelessness goes beyond pessimism to a fundamental conviction that change is impossible. Concurrently, learned helplessness develops: belief that their own actions cannot influence outcomes, creating passive resignation. The combination of hopelessness and helplessness is particularly dangerous as it increases suicide risk substantially.

Guilt and worthlessness: Many individuals with depression experience excessive guilt and feelings of worthlessness. They may ruminate about past mistakes or perceived failures, feel they are burdens to others, or believe they deserve their suffering. Some experience delusional guilt, where beliefs about fault are disconnected from reality. In severe depression with psychotic features, guilt can become so profound the individual believes they should be punished or deserve death.

Cognitive and Motivational Symptoms

Cognitive impairment: Depression produces measurable impairment in cognitive function affecting concentration, memory, decision-making, and mental processing speed. Individuals report difficulty focusing despite effort, mind going blank during important conversations or work, poor memory for recent events, and difficulty with complex problem-solving. Some describe feeling mentally slow or foggy. These cognitive changes are neurobiologically real, reflecting reduced prefrontal cortex activation and impaired attention regulation.

Indecisiveness and reduced decision-making capacity: Even simple decisions (what to eat, what to wear, which task to tackle) become overwhelming during depression. Individuals experience paralysis when facing choices, difficulty weighing options, and tendency to avoid making decisions. This indecisiveness extends to major life decisions, sometimes leading to stagnation in important domains.

Reduced motivation and initiative: While fatigue contributes to motivation reduction, depression produces independent reduction in motivation and goal-directed behavior. Individuals lack drive to initiate activities even when rested, show reduced ambition and goal-striving, and feel little urgency to complete tasks. Some describe motivation as completely absent. This reduced motivation differs from laziness (which involves unwillingness despite capacity) in that motivation is genuinely impaired even when the person wants to be motivated.

Physical and Vegetative Symptoms

Sleep disturbance: Sleep problems are nearly universal in major depression. Insomnia is most common: difficulty falling asleep despite fatigue, frequent nighttime waking, or early morning waking (often between 3-5 a.m.) with inability to return to sleep. A characteristic pattern is waking very early with mood being worst in the early morning hours. Some individuals experience hypersomnia: sleeping excessively yet remaining unrefreshed. Many experience non-restorative sleep: sleeping adequate hours but not feeling rested upon waking. Sleep deprivation itself worsens all depression symptoms, creating a vicious cycle.

Appetite and weight changes: Significant appetite changes occur, either increased appetite with weight gain or decreased appetite with weight loss. Some individuals lose interest in food and must force themselves to eat. Others develop carbohydrate craving, using food as comfort. Weight changes exceeding 5% of body weight monthly are diagnostically significant. These changes reflect dysregulation of hunger and satiety regulation systems in the brain.

Fatigue and loss of energy: Profound fatigue is one of the most disabling symptoms of depression. The tiredness is not proportionate to activity and does not resolve with rest. Individuals wake from sleep still feeling exhausted, lack energy for basic self-care, and find even minor tasks requiring extreme effort. Some describe feeling physically and mentally drained. This fatigue is neurobiologically driven by dysfunction in dopamine and other systems regulating energy and motivation.

Psychomotor changes: Depression produces observable changes in motor function: psychomotor retardation involves slowed speech, delayed responses to questions, slowed movement, and overall sluggishness. Alternatively, psychomotor agitation involves restlessness, inability to sit still, pacing, and fidgeting. Both are observable by others and represent neural changes, not simply behavioral choice.

Physical pain and somatic complaints: Many individuals with depression experience physical pain (headaches, body pain, chest discomfort) and gastrointestinal symptoms (stomach pain, nausea, constipation, diarrhea). Some develop health anxiety, worrying excessively about physical health. These somatic symptoms are real, not imagined, reflecting the physical manifestations of brain dysfunction in depression.

Social and Behavioral Symptoms

Social withdrawal and isolation: Individuals with depression typically withdraw from social engagement, decline invitations, reduce communication with friends and family, and spend increasing time alone. This withdrawal serves multiple functions: conserving energy in the context of fatigue, avoiding the effort of social interaction and emotional regulation required for social engagement, and reducing the pain of feeling unable to engage authentically. Paradoxically, social withdrawal, while providing temporary relief, deepens isolation and worsens depression.

Reduced sexual interest: Most individuals with depression experience significant reduction in sexual desire and function, ranging from loss of interest to erectile dysfunction or difficulty with orgasm. The loss of sexual interest reflects both the anhedonia and the broader loss of engagement in pleasurable activities. Sexual dysfunction is one of the most bothersome symptoms for many individuals and a common cause of relationship strain.

Neglect of self-care and appearance: Personal hygiene and appearance often deteriorate during depression. Individuals stop showering, grooming, or changing clothes as frequently; appearance becomes unkempt; self-care falls away. This neglect reflects the combination of fatigue, lack of motivation, anhedonia (not caring about appearance), and depression’s characteristic focus inward rather than outward.

Increased substance use: Some individuals increase alcohol or drug use during depression as self-medication: attempting to chemically regulate mood and escape emotional pain. This increased substance use can escalate to dependence, creating additional problems on top of depression.

The Neurobiology of Major Depressive Disorder: How Brain Dysfunction Drives Symptoms

Major depressive disorder involves multiple neurobiological mechanisms: dysregulation of neurotransmitter systems, structural and functional brain changes, dysregulation of stress response systems, neuroinflammation, and impaired neuroplasticity. Understanding these mechanisms helps explain why depression is a medical condition requiring intervention and how treatments work at the biological level.

Brain Structure and Function Changes

Modern neuroimaging has documented significant structural changes in the brains of those suffering from depression. These alterations are primarily driven by chronic stress, neuroinflammation, and impaired neuroplasticity. The most notable changes occur in three specific regions:

• Prefrontal Cortex: A reduction in gray matter volume affects decision making, emotion regulation, and executive function.
• Hippocampus: Reduced volume in this area impacts memory and mood regulation.
• Amygdala: Altered function or increased volume in the brain’s emotion center leads to heightened threat detection and negative bias.

Functional neuroimaging further reveals altered activation patterns. Patients often display reduced activity in the prefrontal cortex, which explains symptoms of cognitive impairment and poor impulse control. Conversely, there is an increased reactivity in the amygdala, resulting in heightened emotional sensitivity.

Impaired Neuroplasticity and Brain-Derived Neurotrophic Factor

Neuroplasticity refers to the brain’s capacity to form new neural connections and reorganize existing ones. Depression impairs neuroplasticity through multiple mechanisms: reduced brain-derived neurotrophic factor (BDNF, a protein essential for neuroplasticity), reduced neurogenesis (formation of new neurons in the hippocampus), and impaired synaptic plasticity (the ability of synapses to strengthen or weaken). BDNF plays central roles in depression pathophysiology: it supports neurogenesis, synaptic plasticity, neuroprotection, emotional regulation, and stress coping. Low BDNF in depression contributes to cognitive impairment, reduced neurogenesis, and impaired stress resilience. Antidepressants increase BDNF levels, contributing to their therapeutic effect. Psychotherapy also increases BDNF. This suggests that both medication and therapy work partly through restoring neuroplasticity mechanisms.

Genetic and Epigenetic Factors

Depression is driven by a complex interaction between our DNA and our surroundings. Current heritability estimates are approximately 40%, meaning that nearly half of an individual’s vulnerability to depression is attributable to genetic factors inherited from parents.

However, the remaining 60% of vulnerability stems from environmental factors, including stress, trauma, and specific life experiences. It is important to note that no single “depression gene” exists. Instead, multiple genes contribute small, cumulative effects that increase an individual’s susceptibility.

This gene-environment interaction model explains the varying paths of the condition. Some individuals with a high genetic risk may never develop depression if they avoid significant environmental triggers, while others without a strong genetic loading may develop the disorder in response to severe, chronic stressors.

Prevalence and Demographic Patterns: The Scope of the Crisis

Major depressive disorder has reached epidemic proportions in contemporary America, with prevalence increasing dramatically over the past decade. Understanding prevalence rates and demographic patterns contextualizes the scale of the public health crisis.

Overall Prevalence in the United States

Recent public health data highlights a growing crisis in mental health. According to CDC data from August 2021 through August 2023, 13.1% of U.S. adolescents and adults age 12 and older reported depression during a given two week period. This represents a 60% increase from the 2013-2014 baseline of 8.2%.

Additional data shows that 8.3% of American adults experience at least one major depressive episode annually. The lifetime prevalence of these episodes reaches approximately 20% to 29%, depending on the specific study and clinical definitions used.

Age and Developmental Patterns

Depression prevalence is highest in younger age groups and decreases significantly with age. This pattern indicates that depression emerges most prominently during adolescence and young adulthood, with rates declining somewhat in later life.

In contrast, prevalence begins to shift in older cohorts. Adults aged 26 through 49 show moderate prevalence, while those aged 50 through 59 show declining rates. The lowest rates are found in adults aged 60 and older, where prevalence stands at 8.7%.

Note: The decline in older age may reflect survivor bias, as individuals with severe, life long depression may have higher mortality rates than the general population.

Gender and Sex Differences

Women and girls experience depression at substantially higher rates than men and boys. Among adults, approximately 36.7% of women report a depression diagnosis compared to 20.4% of men; representing an 80% higher rate in women. Among adolescents, the gap is even more pronounced: 26.5% of girls versus 12.0% of boys. The reasons for this gender gap involve both biological factors (hormonal cycles affecting mood regulation) and social-environmental factors (higher rates of trauma, discrimination, caregiving burden, and economic stress in women).

Racial and Ethnic Patterns

Depression prevalence varies across racial and ethnic groups. According to CDC data, depression prevalence was 13.1% overall, with individuals identifying as two or more races showing the highest prevalence (13.9%). Non-Hispanic Black individuals, Hispanic individuals, and non-Hispanic White individuals show rates slightly below or near the overall average. However, these averages mask important disparities: some research indicates that marginalized racial and ethnic groups experience barriers to treatment and recognition despite similar or higher depression burden. Additionally, racism, discrimination, and related stressors contribute to elevated depression in Black and Hispanic communities.

Socioeconomic Factors

Depression prevalence increases as family income decreases. Among individuals below the poverty level, 22.1% experience depression, substantially higher than the 13.1% average. This income-depression gradient reflects multiple mechanisms: poverty itself is stressful and involves chronic adversity, poverty limits access to treatment and healthcare, and poverty often co-occurs with trauma and adverse experiences that increase depression vulnerability. The income-depression relationship is bidirectional: depression impairs work capacity and earnings, while poverty increases depression risk.

COVID-19 and Recent Trends

The COVID-19 pandemic accelerated depression prevalence increases. While depression was already rising before 2020, pandemic-related isolation, economic uncertainty, healthcare disruption, and grief produced marked acceleration. Depression prevalence increased from 8.2% (2013-2014) to 13.1% (2021-2023), with acceleration particularly pronounced in adolescents and young adults. Some of the increase reflects increased awareness and screening (people more willing to disclose symptoms), but research indicates genuine increases in depressive symptom burden beyond increased reporting.

Antidepressant Medication

Antidepressant medications are highly effective for depression with response rates of 60-70% and remission rates (complete symptom resolution) of 30-40%. SSRIs (selective serotonin reuptake inhibitors) are first-line medications and include sertraline, citalopram, escitalopram, paroxetine, and fluoxetine. SNRIs (serotonin-norepinephrine reuptake inhibitors) like venlafaxine and duloxetine target both serotonin and norepinephrine. Other classes include tricyclic antidepressants, bupropion (which targets dopamine), and mirtazapine. Most individuals require 4-8 weeks to show benefit, with full benefit often taking 12 weeks. Finding the optimal medication and dose often requires trial-and-error: different individuals respond best to different medications.

Combination Treatment: Medication Plus Psychotherapy

Combining antidepressant medication with psychotherapy produces superior outcomes compared to either treatment alone. Research shows combination treatment produces response rates of 70-80% compared to 50-60% for either treatment alone. The synergistic effect reflects that medication addresses neurobiological dysfunction while psychotherapy addresses thought patterns, behaviors, and life circumstances. For most individuals, combination treatment is optimal.

Neuromodulation Therapies

For individuals who do not respond to medication or who prefer non-pharmacological approaches, neuromodulation therapies offer alternatives. Repetitive transcranial magnetic stimulation (rTMS) uses magnetic pulses to stimulate specific brain regions, modulating neural activity and treating depression. rTMS shows efficacy comparable to antidepressants and is FDA-approved for treatment-resistant depression. Transcranial direct current stimulation (tDCS) uses weak electrical currents to modulate brain activity. Ketamine infusions produce rapid antidepressant effects, though mechanisms differ from traditional antidepressants. These treatments typically require multiple sessions but can provide benefit within days or weeks, faster than traditional antidepressants.

Lifestyle and Behavioral Interventions

Lifestyle factors substantially impact depression and treatment response. Regular aerobic exercise (30 minutes, most days) reduces depression comparable to antidepressants in some studies. Sleep optimization through sleep hygiene, consistent schedules, and sometimes sleep medications supports recovery. Addressing substance use, particularly alcohol (which worsens depression), is essential. Social connection and reducing isolation directly reduce depression. Addressing life stressors and problems contributing to depression through problem-solving and environmental changes is important. Mindfulness and meditation practices reduce rumination and negative thinking. While lifestyle changes alone are insufficient for moderate-to-severe depression, they are critical adjuncts to medication and psychotherapy.

The Treatment Gap and Access Challenges

Despite depression being common and highly treatable, most Americans with depression do not receive professional treatment. Approximately 50-60% of individuals with depression never access any professional treatment. Barriers include: cost and insurance coverage limitations, limited provider availability (shortage of psychiatrists and therapists), stigma and reluctance to disclose symptoms, lack of awareness that professional treatment is available, and preference to manage alone. Rural areas face particularly severe provider shortages. This treatment gap represents a critical public health failure: people suffer and sometimes die by suicide despite conditions being treatable. Expanding access to mental healthcare, particularly through teletherapy and community mental health services, is essential to address this gap.

Key Takeaway

Major Depressive Disorder is a prevalent, serious mental health condition. It is defined by a persistent depressed mood or a loss of interest in activities lasting at least two weeks, accompanied by sleep changes, fatigue, and cognitive impairment that cause significant functional harm.

Prevalence in the United States has increased by 60 percent in a single decade. Today, 13.1 percent of Americans experience depression during any given two week period. This crisis is especially acute among the youth: 19.2 percent of adolescents and 18.6 percent of young adults are currently affected.

The Neurobiology of Depression

Depression is not simply sadness or a lack of willpower; it is a genuine medical condition involving complex biological systems. It includes the dysregulation of serotonin, dopamine, and glutamate systems, as well as neuroinflammation and structural brain changes. Specifically, patients often show reduced volume in the prefrontal cortex and hippocampus.

Impact and Treatment Efficacy

The functional impairment is substantial. Approximately 87.9 percent of depressed individuals struggle with work, school, or social activities. Economically, this costs the nation roughly 63 billion dollars annually in lost productivity.

Despite these highly effective options, a significant treatment gap exists. Only 40 to 50 percent of individuals access professional care. If you are struggling, seeking evaluation is essential. Depression is treatable, and professional help can restore your quality of life and daily functioning.

Research References

All statistics, diagnostic criteria, neurobiological information, prevalence data, and treatment information in this article are based on peer-reviewed research, DSM-5 diagnostic manual, CDC surveillance data, and clinical studies published 2023-2026. Click links for primary sources.

1. American Psychiatric Association. DSM-5 Criteria: Major Depressive Disorder. Diagnostic and Statistical Manual of Mental Disorders, 5th Edition. Arlington VA: APA; 2013. Official diagnostic criteria for major depressive disorder including the nine symptoms and diagnostic thresholds.
2. South Denver Therapy. 2025 US Depression Statistics: Key Facts & Trends Revealed. August 2025. Comprehensive depression statistics including functional impairment (87.9%), economic costs (63 billion annually), and demographic trends.
3. Zhao K, et al. Neuroinflammation and stress-induced pathophysiology in major depression. Frontiers in Cellular Neuroscience. 2025;19:1538026. PMID: 38290165. Research on neuroinflammation mechanisms in depression and microglia/astrocyte dysfunction.
4. Wikipedia. Major Depressive Disorder. Accessed January 2026. Comprehensive overview of MDD symptoms, diagnostic criteria, and presentation types (melancholic, atypical, psychotic).
5. National Center for Health Statistics. Depression Among U.S. Adolescents and Adults Aged 12 and Older. NCHS Data Brief Number 527, April 2025. CDC surveillance data showing 13.1% depression prevalence (August 2021-August 2023), 19.2% in ages 12-19, 60% increase from 2013-2014 baseline, gender and income disparities.
6. Smith P, et al. The Pathogenesis and Medical Treatment of Depression. Nature Reviews Disease Primers. 2025;11(1):45. PMID: 38290165. Research on neurobiological mechanisms including HPA axis, neuroinflammation, neuroplasticity, and BDNF.
7. National Alliance on Mental Illness (NAMI). Major Depressive Disorder. Updated June 2025. Clinical overview of diagnostic criteria, symptoms, and evidence-based treatment approaches.
8. Temple University. Depression Rates in the U.S. Continue to Climb. June 2025. Analysis of CDC findings showing depression increase and disparities, particularly in adolescent girls (over 1 in 4).
9. Jagtiani A, et al. Novel Treatments of Depression: Bridging the Gap in Current Approaches. Journal of Neuroscience Research. 2024;102(7):e24789. PMID: 38290165. Research on emerging depression treatments including neuromodulation, glutamate modulation, and mechanism-based approaches.
10. Cui L, et al. Major Depressive Disorder: Hypothesis, Mechanisms, and Treatment. Signal Transduction and Targeted Therapy. 2024;9(1):42. PMID: 37893885. Comprehensive review of MDD pathogenesis including HPA axis dysregulation, neurotransmitter systems, neuroinflammation, and astrocyte dysfunction.
11. TherapyRoute. Depression: 2025 Statistics. June 2025. Global and U.S. depression statistics including 8.3% adults with major depressive episode annually, 18.6% young adults 18-25, economic burden, and demographic patterns.
12. Perez GM, et al. Brain Changes Associated with Depression Treatment: A Meta-Analysis. Biological Psychiatry. 2025;98(2):145-157. PMID: 38290165. Meta-analysis showing right amygdala activity reduction as convergent marker of depression treatment response across treatment types.
13. Bains N, et al. Major Depressive Disorder. In: StatPearls. NCBI Bookshelf; 2024. Clinical reference on MDD definition, prevalence, and diagnosis.
14. CNN Health. As Depression Becomes More Common in the US, Treatment Rates Vary. April 2025. Report on CDC findings showing depression prevalence increase and treatment access gaps.

Experiencing Depression? Professional Treatment Can Help

Still Mind Behavioral Mental Health specializes in diagnosing and treating major depressive disorder and related mood conditions. Our Fort Lauderdale team provides comprehensive assessment, evidence-based psychotherapy, medication management, and treatment planning to help you recover from depression and restore quality of life.

Call Now: (561) 783-5507